Seattle Genetics, Inc. (Seattle Genetics), an in vitro diagnostics company, has appointed Vaughn Himes as executive vice president (EVP), technical operations. Vaughn Himes brings to Seattle Genetics more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. The company also promoted Morris Rosenberg to executive vice president, process sciences.
Morris Rosenberg joined Seattle Genetics in July 2001 and has overseen significant growth of the company’s development organization, including the process development, quality assurance and control, analytical biochemistry, formulation and manufacturing functions. Previously, Rosenberg was with Eli Lilly, Biogen and Invitron.
Previously, Vaughn Himes was with Zymogenetics, Inc., most recently as senior vice president, technical operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development.
“We are continuing to strengthen our management team and position the company to deliver on our substantial product development goals, including the planned commercial launch of SGN-35 in 2012,” said Clay B. Siegall, president and chief executive officer of Seattle Genetics. “Vaughn brings a strong background in commercial manufacturing and supply chain management, and has been involved in several successful drug approval submissions. Morris continues to demonstrate substantial operational expertise and leadership as Seattle Genetics has advanced its broad product pipeline into late-stage clinical trials. Together, these seasoned executives will play a key role in guiding our development and manufacturing initiatives across our pipeline, including our SGN-35 new drug application.”
Regarding Senter’s recognition as Distinguished Fellow, Siegall added, “Peter is a world-renowned research scientist and leader in the field of antibody-drug conjugates (ADCs). His body of work, including his key role with SGN-35 and the company’s ADC technology, provides evidence of his significant impact on Seattle Genetics and the global scientific community.”